Indaptus Therapeutics is trading at $0.98 (-8.40%) on August 17, 2026, following its August 13 second-quarter report and corporate update, alongside the discontinuation of further Decoy20 enrollment.
- No Decoy20 participants remain, and the company has no active clinical development programs.
- Management is pivoting toward neurology and reviewing strategic alternatives.
- Cash and short-term investments totaled $11.6 million; the earnings report is the clearest company-specific catalyst, with no separate August 17 announcement found.